Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIT-HF
2023-503753-35-01Phase 2Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of semaglutide in obesity and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Capital Region of Denmark. Primary endpoint: Change in peak oxygen uptake. Planned start Mar 2024; status: authorised.
02
Drugs
03
Conditions
obesityheart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2023-503753-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503753-35-01.